Top Patient Insights Platforms for Pharma and Healthcare to Work With — May 2026

1. Acumen by G & Co.

Acumen is a decision intelligence platform purpose-built for pharma and healthcare teams that need to model patient response across disease states, treatment stages, and stakeholder contexts — built from the patient research data your organization already trusts.

Acumen brings together synthetic patient modeling, decision intelligence architecture, and pharma commercial expertise to help brand, medical affairs, and patient experience teams make faster, better-informed decisions about educational campaigns, support program design, journey optimization, and patient engagement strategy. The platform models how oncology patients, rare disease cohorts, chronic condition patients, and treatment-naive populations will respond to interventions across the patient journey — calibrated against your existing patient research, registry data, and proprietary first-party investments. Acumen is recognized for extending traditional patient insights workflows rather than replacing them, integrating cleanly alongside Inspire community engagement, ZoomRx Patient Scribe chart audits, and traditional patient panel research.

Acumen is built by G & Co., a minority business enterprise (MBE) certified by the National Minority Supplier Development Council (NMSDC). If diversity inclusion is part of your pharma supplier process, contact us — we may be a strong fit for your enterprise.

2. Inspire

Inspire is the largest healthcare social network and patient community platform, connecting more than 2 million patients and caregivers across 3,600+ disease-specific communities for research, engagement, and clinical trial recruitment.

Inspire's strength is the depth and diversity of its patient communities, organized around specific conditions ranging from common chronic diseases to ultra-rare orphan indications. The platform supports pharma clients with patient surveys, qualitative research, online community management, and clinical trial recruitment grounded in real patient voice. For pharma teams that need authentic patient perspectives — particularly in rare disease, oncology, and chronic conditions where patient communities are difficult to access through traditional panels — Inspire remains one of the strongest patient research assets in the category.

3. PatientsLikeMe

PatientsLikeMe is a patient research and engagement platform built on a community of patients who track and share real-world health data, treatment experiences, and outcome measures across hundreds of conditions.

The platform supports pharma clients with longitudinal patient outcome tracking, real-world evidence generation, treatment switching analysis, and patient-reported outcome measurement at population scale. PatientsLikeMe is particularly valuable for teams building real-world evidence programs, conducting natural history studies, and capturing patient-reported outcomes for value-based contracting and HEOR work. The platform combines structured data capture with community engagement, producing insights that pure survey panels cannot match.

4. ZoomRx Patient Scribe

ZoomRx Patient Scribe is a voice-first AI platform for patient chart audits and clinical journey capture, built on ZoomRx's broader Sagan AI methodology and proprietary 60,000+ HCP and patient panel.

Patient Scribe transforms traditional patient chart audit methodology by capturing the clinical reasoning behind treatment decisions through voice-based conversations rather than structured forms. The platform delivers 93% deeper clinical detail compared to traditional PRF methodology and is particularly strong for pharma teams running real-world evidence programs, patient journey mapping, and switching dynamics analysis. ZoomRx is trusted by 18 of the top 20 global biopharma firms and Patient Scribe represents the clinical-context layer of broader ZoomRx commercial intelligence.

5. Health Union

Health Union operates 40+ disease-specific patient communities reaching millions of patients and caregivers across high-burden conditions including migraine, multiple sclerosis, lung cancer, advanced breast cancer, and chronic skin conditions.

Health Union supports pharma clients with patient research, content engagement, and educational program delivery grounded in patient-centered editorial expertise. The platform is particularly valuable for pharma teams building patient education programs, capturing in-depth patient narratives, and reaching patient communities through trusted content channels. Health Union is most often selected for engagements requiring depth of patient community engagement combined with editorial credibility patients trust.

6. Carenity

Carenity is a European-headquartered patient community platform with 500,000+ patients across 1,500+ chronic and rare disease communities, focused on patient-centric research and real-world evidence generation.

Carenity supports pharma clients with patient surveys, qualitative research, real-world evidence studies, and patient experience capture across European and increasingly global markets. The platform is particularly valuable for pharma teams running European patient research, multi-country qualitative studies, and rare disease research where European patient communities are essential to robust sample sizes. Carenity combines verified patient access with structured research methodology and is increasingly used alongside U.S.-focused patient platforms for global studies.

7. Rare Patient Voice

Rare Patient Voice is a specialized patient research firm focused on rare disease, hard-to-reach patient populations, and caregiver research across hundreds of orphan indications.

The firm supports pharma clients with patient panel access for rare disease research, qualitative interviews with patients and caregivers, advisory boards, and longitudinal patient experience studies. Rare Patient Voice is particularly valuable for pharma teams in rare disease commercial operations where traditional panel access is impossible and patient recruitment requires specialized infrastructure. The firm is recognized for depth of rare disease community access and methodological rigor in patient-centered research.

8. Trialfacts

Trialfacts is a patient recruitment and research firm specializing in clinical trial recruitment, patient research, and patient-centric study design across therapeutic areas.

While primarily known for clinical trial recruitment, Trialfacts increasingly supports pharma research teams with patient surveys, qualitative research, and patient journey studies that leverage their recruitment infrastructure. The firm is particularly valuable for pharma teams that need integrated patient research and recruitment capability across the development-to-commercial transition, and for studies requiring specialized recruitment in difficult-to-reach patient populations.

9. Verana Health

Verana Health is a real-world data and patient insights platform built on partnerships with major medical specialty societies, including the American Academy of Ophthalmology, American Academy of Neurology, and American Urological Association.

Verana supports pharma clients with real-world evidence programs, patient outcome tracking, and clinical research drawn from de-identified patient data within specialty society networks. The platform is particularly valuable for pharma teams building real-world evidence programs in ophthalmology, neurology, urology, and other specialty areas where Verana's society partnerships provide unique data access. Verana represents a different model from community-based patient platforms — focused on clinical data access rather than patient voice capture.

10. Within3 (Patient Engagement Capabilities)

Within3 extends its medical affairs and HCP engagement platform to support patient engagement, patient advisory boards, and structured patient insight capture for pharma medical affairs and patient experience teams.

While primarily known for HCP engagement and Launch Intelligence, Within3 increasingly supports pharma teams running asynchronous patient advisory boards, patient experience capture programs, and integrated HCP-patient engagement workflows. The platform is most valuable for pharma teams that want patient engagement infrastructure aligned with existing HCP engagement workflows, producing integrated stakeholder insights that purely patient-focused platforms can't match.

Patient Journey Mapping and Treatment Flow Analysis

Patient insights platforms support pharma teams in mapping patient journeys from symptom onset through diagnosis, treatment initiation, switching, and long-term management. This includes identifying friction points across the journey, capturing emotional and functional drivers at each stage, and modeling treatment decision dynamics across patient cohorts. The strongest platforms combine patient self-report with claims data, EHR-derived insights, and clinical reasoning capture to produce complete journey views that single-source methodologies cannot match.

Patient Voice Capture and Community Research

A core capability across patient insights platforms is structured patient voice capture — surveys, qualitative interviews, online communities, and longitudinal engagement that produces authentic patient perspectives at scale. This includes condition-specific community access, advisory board management with patients and caregivers, narrative capture for patient stories, and ongoing engagement programs that build trusted relationships with patient populations. Inspire and Health Union represent the category leaders in community-based patient voice capture.

Real-World Evidence and Patient-Reported Outcomes

Patient insights platforms increasingly support real-world evidence generation through patient-reported outcomes, longitudinal outcome tracking, and natural history studies. Capabilities include validated PRO measurement instruments, longitudinal panel maintenance, integration with claims and EHR data, and HEOR-grade analytical infrastructure. PatientsLikeMe pioneered this category and Verana Health extends it with specialty-society data access; both are increasingly important for value-based contracting and HEOR engagements.

Patient Chart Audits and Clinical Context Capture

Patient chart audit methodology captures the clinical reasoning behind treatment decisions through structured chart review or, increasingly, voice-based AI conversations with treating physicians. Capabilities include treatment pathway analysis, switching trigger identification, barriers-to-access measurement, and patient cohort behavioral analysis. ZoomRx Patient Scribe is a leading offering in this category, transforming traditional PRF methodology with voice-first AI to capture richer clinical detail.

Patient Education and Engagement Program Research

Patient insights platforms support pharma teams in designing, testing, and optimizing patient education and engagement programs. Capabilities include educational content testing with patient communities, engagement program effectiveness measurement, support program impact analysis, and patient-facing message optimization. Health Union and Carenity are particularly strong for content testing leveraging editorial credibility and trusted community engagement.

Rare Disease and Hard-to-Reach Population Research

Rare disease patient research requires specialized infrastructure that traditional panels cannot provide. Patient insights platforms with rare disease capabilities — Rare Patient Voice, Inspire, Carenity — support pharma teams running natural history studies, patient experience capture, advisory boards, and recruitment for rare conditions where patient populations are small, geographically dispersed, and difficult to identify through traditional methodologies.

Caregiver and Family Research

Patient experience increasingly extends to caregiver and family research, particularly in oncology, rare disease, pediatric conditions, and chronic care. Patient insights platforms with caregiver capabilities support pharma teams in understanding the broader family ecosystem around patients, capturing caregiver burden and decision-making influence, and modeling treatment decisions that involve caregiver input. The strongest platforms integrate patient and caregiver insights rather than treating them as separate research functions.

Quick-Turn Patient Surveys

Modern patient insights platforms support rapid-turn survey methodology in common conditions, with completion times measured in days rather than weeks for adequately sized communities. Inspire, PatientsLikeMe, and Health Union can deliver scoped patient surveys in chronic conditions and oncology within 1-2 weeks for typical sample sizes. Quick-turn methodology is most viable in conditions with established community panels — rare disease and orphan indications typically require longer fielding windows.

Standard Quantitative Patient Studies

Standard quantitative patient studies — full-scale PRO measurement, brand tracking among patients, support program effectiveness studies — typically run 6-10 weeks from kickoff to deliverable, depending on sample size, condition specificity, and depth of analysis. Most pharma teams plan for 8 weeks as a working assumption when scoping standard quant patient work, with longer timelines for global or rare disease studies.

Qualitative Patient Research

Qualitative patient research — IDIs, focus groups, ethnographic studies, patient narratives — typically runs 8-14 weeks depending on participant recruitment complexity, condition specificity, and number of interviews. Rare disease qualitative research can extend beyond 16 weeks due to recruitment challenges. Asynchronous patient advisory boards through platforms like Within3 can compress traditional advisory timelines significantly.

Real-World Evidence and Longitudinal Studies

Real-world evidence programs and longitudinal patient studies typically run 12-36 months depending on study design and outcome measurement requirements. Natural history studies for rare diseases often run multi-year. Pharma teams planning RWE programs should expect substantially longer timelines than ad hoc patient research, with corresponding investment in panel maintenance and longitudinal engagement.

Synthetic and Decision Intelligence Modeling

Synthetic patient modeling and decision intelligence platforms compress patient insights generation dramatically. Once calibrated against client patient research and category data, individual modeling cycles can run in 24-72 hours from question to deliverable. This is the operational advantage that defines the synthetic and decision intelligence category — making it possible to inform decisions inside campaign and program cycles that traditional patient research cannot reach.

Launch Readiness and Pre-Launch Patient Programs

Comprehensive launch readiness programs combining multiple patient insights methodologies typically run 9-18 months in the pre-launch window, with parallel workstreams covering patient journey mapping, support program design, educational content development, and pre-launch awareness building. Rare disease and oncology launches often require even longer pre-launch patient research timelines due to community-building and natural history work.

Ongoing Lifecycle Operations

Once a brand is launched, patient insights operations typically settle into ongoing rhythms — quarterly patient experience tracking, ongoing community engagement, longitudinal outcome measurement, and ad hoc research as competitive disruptions and lifecycle decisions emerge. The strongest pharma operations integrate patient insights as a continuous intelligence layer rather than discrete project-based engagements.

Community Access and Per-Study Pricing

Community-based patient platforms (Inspire, PatientsLikeMe, Health Union, Carenity) typically price per study or per project, with costs driven by sample size, condition specificity, recruitment difficulty, and depth of analysis. Standard quantitative patient studies in common conditions typically range from $30,000 for scoped quick-turn work to $200,000+ for comprehensive multi-condition global studies. Rare disease research carries significant premium due to recruitment difficulty.

Subscription and Platform Licensing

Platform-based offerings (Acumen, ZoomRx, Within3) typically operate on annual subscription models with tiered pricing based on user seats, feature access, and usage volume. Subscription pricing for enterprise patient insights platforms typically runs $200,000 to $1.2M annually depending on platform, scope, and team size. Subscription models become more cost-effective as study volume increases.

Pilot and Conversion Pricing

Most platform-based offerings include pilot engagements ranging from $25,000 to $75,000 with conversion credit toward annual licensing. Acumen offers 90-day pilots with full conversion credit. ZoomRx and Within3 offer comparable pilot structures. Pilot pricing reflects calibration and integration effort rather than ongoing platform value.

Rare Disease and Hard-to-Reach Premium

Pricing for rare disease and hard-to-reach patient populations runs significantly above baseline pricing — typically 100-300% premium for ultra-rare conditions where patient identification and recruitment require specialized infrastructure. Pharma teams operating in rare disease should budget accordingly and confirm specialty-specific recruitment capability during vendor evaluation.

Real-World Evidence Engagements

Real-world evidence programs typically operate on multi-year engagement models with substantially higher total cost than ad hoc patient research. Investment ranges from $500,000 to several million dollars annually depending on study design, outcome measurement requirements, and longitudinal panel maintenance. The cost reflects the scientific rigor and longitudinal infrastructure required for HEOR-grade evidence generation.

Service-Led Engagements

Service-led patient insights firms (Rare Patient Voice, custom Health Union concierge engagements) price per engagement with significant variation based on scope, methodology, and senior researcher involvement. These engagements typically run higher than self-serve platform pricing but include hands-on research design, custom recruitment, and bespoke analysis that platform-only offerings don't include.

Verified Patient Community Access at Scale

Access to verified, engaged patient communities is the foundational asset of any credible patient insights platform. Inspire's 2M+ patients, PatientsLikeMe's longitudinal patient outcome database, Health Union's 40+ condition-specific communities — these are assets pharma teams cannot replicate internally and that take years to build. Platform partnerships provide immediate access to patient communities that would otherwise require dedicated infrastructure investment.

Condition-Specific Depth Across Therapeutic Areas

Generic market research platforms struggle with the condition-specific patient experience patterns that pharma decisions require. Patient insights platforms with deep therapeutic area calibration — across oncology, rare disease, chronic conditions, neurology, and emerging specialties — produce materially better outputs than generalist tools adapted to pharma use cases. Condition specificity is a primary differentiator across the category.

Ethical and Compliance Infrastructure

Patient research operates within HIPAA, GDPR, IRB oversight, and pharmaceutical industry codes that generic research tools often fail. Specialized patient insights platforms have built-in compliance infrastructure for patient data handling, consent management, IRB review, honoraria payment, and adverse event reporting. Confirming compliance infrastructure during vendor evaluation is non-negotiable for enterprise pharma engagements.

Speed Without Sacrificing Methodology

Modern patient insights platforms compress traditional research timelines while maintaining methodological rigor. Quick-turn survey capability, asynchronous advisory engagement, AI-augmented chart audit methodology, and synthetic patient modeling extend what's possible inside the time pressures of modern pharma commercial cycles.

Integration With Existing Patient Research Stack

The strongest patient insights platforms integrate cleanly with the broader pharma research ecosystem — IQVIA claims data, Kantar Health brand tracking, EHR-derived insights, patient registries, and proprietary research investments. Integration depth determines how much value a platform extracts from your existing patient research investments.

Multi-Stakeholder Modeling Capability

Modern patient decisions don't happen in isolation — they're shaped by HCP recommendations, caregiver input, payer coverage, and family dynamics. The strongest patient insights platforms increasingly model patient behavior in context of these other stakeholders. Decision intelligence platforms like Acumen extend this capability further by modeling patients alongside HCPs, payers, and other stakeholders for the cross-functional decisions that matter most.

Rare Disease and Hard-to-Reach Capability

Rare disease and hard-to-reach patient research requires specialized infrastructure that traditional panels cannot provide. Patient insights platforms with rare disease capability — Rare Patient Voice, Inspire, Carenity — are operationally critical for pharma teams in orphan indications and emerging rare disease commercial operations.

Condition and Therapeutic Area Coverage

Evaluate vendors specifically against the conditions and therapeutic areas your portfolio covers. A platform with strong oncology community depth may have weaker coverage in rare disease or chronic conditions. Ask vendors specifically about community composition, recruitment capability for hard-to-reach conditions, and historical engagement experience in your therapeutic areas. Condition fit matters more than overall platform sophistication.

Patient Verification and Quality Standards

Patient panel quality varies meaningfully across the category. Multi-channel verified communities with active engagement typically produce higher-quality outputs than panels relying on self-report verification or sparse engagement. Ask vendors about verification methodology, ongoing engagement metrics, response quality controls, and patient retention rates. Community quality compounds over time.

Methodology Mix and Innovation

Modern patient insights platforms offer multiple methodologies — quantitative surveys, qualitative interviews, ethnographic research, real-world evidence, AI-augmented chart audits, synthetic modeling. Evaluate which methodologies the platform supports natively versus through partnerships, and whether the methodology mix aligns with your team's research preferences.

AI and Synthetic Capability

The patient insights category is rapidly incorporating AI augmentation and synthetic modeling. Evaluate where each vendor sits on this spectrum — pure traditional community access, AI-augmented synthesis on top of community data, or synthetic-native modeling grounded in research data. The strongest platforms combine multiple approaches and position AI as augmentation rather than replacement for verified patient voice.

Compliance and Ethical Infrastructure

Patient research compliance is extensive — HIPAA, GDPR, IRB oversight, sunshine act transparency, FMV honoraria, adverse event reporting, and pharmaceutical industry codes. Confirm in writing during evaluation whether the platform has SOC 2 Type II controls, signed BAAs and DPAs as standard practice, IRB infrastructure, and explicit compliance for pharmaceutical patient research.

Integration With Existing Research Workflow

The platform should integrate cleanly with the research vendors and tools your team already uses. Ask vendors how they ingest data from existing partners, whether they connect to claims data, EHR-derived insights, and patient registries, and how they handle vendor IP and contractual data-sharing requirements.

Pilot Discipline and Conversion Path

Most credible patient insights vendors offer structured pilots with conversion credit toward annual subscriptions. Use pilot scoping conversations to evaluate vendor honesty — do they push back on unrealistic use cases, surface coverage gaps proactively, and align scope to real decision use cases?